Skip to main content
Clinical Trials/CTRI/2017/05/008662
CTRI/2017/05/008662RecruitingNot Applicable

Clinical evaluation of Laksha Guggulu, Muktasukti Bhasma in the management of Osteopeniea/ Osteoporosis

Central Council for Research in Ayurvedic Sciences2 sites in 1 country60 target enrollmentStarted: March 22, 2017Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Enrollment
60
Locations
2
Primary Endpoint
Improvement in BMDT

Study Overview

Brief Summary

For the scientific validation of classical Ayurvedicformulations a multi centric clinical trial has been initiated for themanagement of Asthisaushirya (Ostoporosis/Osteopenia) as an activity underIntra Mural Clinical Research Programme. Ayurvedic medicines Laksha guggulu,Muktasukthi Bhasma selected for the study. Treatment will be given for 12weeks, Sample size is 60. Duration of the treatment is 12 weeks. Total studyperiod is 2 years.

Study Design

Study Type
Interventional
Allocation
Not Applicable
Masking
Not Applicable

Eligibility Criteria

Ages
45.00 Year(s) to 70.00 Year(s) (—)
Sex
All

Inclusion Criteria

  • •1.Patients of either sex with age above 45years and upto 70 years.
  • •2.B.M.D.T. Score ( -1 to -3) on DEXA Scan 3.Patient willing to participate in the clinical trial.

Exclusion Criteria

  • •1.Patients who are consuming corticosteroids (more than 5mg/day of prednisolone or equivalent) for more than 3 months 2.Patients with history of Fragility Fracture.
  • •3.Patients suffering from congenital disorders related to bone (Dysosteogenesis, Marfan’s Syndrome, etc.) 4.Patients with (Hypothyroidism and Hyperthyroidism, Hypoparathyroidism and Hyperparathyroidism, Cushing‘s syndrome) 5.Patients suffering from Osteomalacia.
  • •6.Patients suffering from Malabsorption syndrome
  • •Patients who have undergone Organ transplantation 8.Patients who are immobilized since > 6 weeks 9.Patients with history of bone fracture in last 6 months.
  • •10.Patients with evidence of malignancy 11.Pregnancy and lactation 12.Patients who cannot report in person once in 2 weeks in the OPD 13.Patients with poorly controlled Hypertension ( >160/100 mmHg) 14.Patients with poorly controlled Diabetes Mellitus having Hb A1C of >8 15.Patients who have a past history of Atrial Fibrillation, Acute Coronary Syndrome, Myocardial Infarction, Stroke or Severe Arrhythmia in the last 6 months.
  • •16.Patients with history of Urolithiasis.
  • •17.Patients with concurrent serious hepatic disorder (defined as Aspartate Amino Transferase (AST) and / or Alanine Amino Transferase (ALT), Total Bilirubin, Alkaline Phosphatase (ALP) > 2 times upper normal limit) or Renal Disorders (defined as S.
  • •Creatinine >1.2mg/dl), Severe Pulmonary Dysfunction (uncontrolled Bronchial Asthma and / or Chronic Obstructive Pulmonary Disease [COPD]), or any other condition that may jeopardize the study.
  • •18.Alcoholics, smokers, and/or drug abusers 19.H/o hypersensitivity to any of the trial drugs or their ingredients 20.Patients who have completed participation in any other clinical trial during the past six months.
  • •21.Patients on calcium and Vitamin D supplementation 22.Known cases of Paget’s disease of bone.
  • •23.Any other condition which the Investigator thinks may jeopardize the study.

Outcomes

Primary Outcomes

Improvement in BMDT

Time Frame: 84th day

Secondary Outcomes

  • Improvement in clinical parameters(84 days)

Investigators

Sponsor Class
Government funding agency

Study Sites (2)

Loading locations...

Similar Trials